{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:33:29Z","timestamp":1770906809893,"version":"3.50.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"National Cancer Institute and National Institutes of Health","award":["P01CA15396"],"award-info":[{"award-number":["P01CA15396"]}]},{"name":"National Cancer Institute and National Institutes of Health","award":["R01CA174951"],"award-info":[{"award-number":["R01CA174951"]}]},{"name":"National Cancer Institute and National Institutes of Health","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.bbmt.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T17:15:26Z","timestamp":1499879726000},"page":"1903-1909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma"],"prefix":"10.1016","volume":"23","author":[{"given":"Nilanjan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Ling","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ephraim J.","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Luznik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lode J.","family":"Swinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard F.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satish","family":"Shanbhag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan M.","family":"Borrello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3088-0964","authenticated-orcid":false,"given":"William","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol Ann","family":"Huff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2017.07.003_bib0010","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0020","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-16-0861","article-title":"Integration of novel agents into the care of patients with multiple myeloma","volume":"22","author":"Orlowski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0025","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1200\/JCO.2000.18.11.2273","article-title":"Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma","volume":"18","author":"Martinelli","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0030","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V96.1.355","article-title":"Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma","volume":"96","author":"Cavo","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0035","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.V87.3.1196.bloodjournal8731196","article-title":"Graft-versus-myeloma effect: proof of principle","volume":"87","author":"Tricot","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0040","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0045","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1200\/JCO.2005.04.5807","article-title":"Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321","volume":"24","author":"Barlogie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0050","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1200\/JCO.2003.04.033","article-title":"Partially T-cell\u2013depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM","volume":"21","author":"Lokhorst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM199110313251802","article-title":"Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation","volume":"325","author":"Gahrton","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","article-title":"Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma","volume":"13","author":"Gahrton","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0065","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/leu.2008.396","article-title":"Role of autologous and allogeneic stem cell transplantation in myeloma","volume":"23","author":"Bensinger","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2141.2001.02726.x","article-title":"Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983\u201393 and 1994\u201398 at European Group for Blood and Marrow Transplantation centres","volume":"113","author":"Gahrton","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0075","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2011-02-337329","article-title":"Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis","volume":"118","author":"Kumar","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0080","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/bmt.2013.73","article-title":"Reduced intensity-conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation","volume":"48","author":"Auner","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0085","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.bbmt.2013.03.012","article-title":"Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry","volume":"19","author":"Passera","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0090","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0095","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0100","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","article-title":"Durable engraftment of major histocompatibility complex\u2013incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide","volume":"98","author":"Luznik","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0105","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1182\/blood-2009-11-251595","article-title":"High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease","volume":"115","author":"Luznik","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0110","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MOH.0b013e32833eaf1b","article-title":"High-dose cyclophosphamide for graft-versus-host disease prevention","volume":"17","author":"Luznik","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0120","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0125","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O'Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0140","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0145","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0150","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0155","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0160","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0165","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J Roy Stat Soc B"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0170","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1182\/blood-2008-12-173526","article-title":"Reduced-intensity allogeneic transplantation for myeloma: reality bites","volume":"113","author":"Stewart","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0175","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1182\/blood-2012-04-420802","article-title":"Death of frontline allo-SCT in myeloma","volume":"119","author":"Moreau","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0180","series-title":"SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)","year":"2012"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0185","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.bbmt.2013.06.008","article-title":"Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"19","author":"Brunner","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0190","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1200\/JCO.2014.60.4777","article-title":"Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults","volume":"33","author":"Kasamon","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0195","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0200","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/sj.bmt.1705131","article-title":"Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation","volume":"36","author":"Chang","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0205","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2005-04-1411","article-title":"Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy","volume":"106","author":"Gertz","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0210","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3324\/haematol.2011.042713","article-title":"Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"96","author":"Roos-Weil","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0215","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/ajh.23412","article-title":"Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma","volume":"88","author":"El-Cheikh","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0220","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/bmt.2014.320","article-title":"Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution","volume":"50","author":"Rosinol","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0225","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.bbmt.2015.04.020","article-title":"Hematopoietic stem cell transplantation in multiple myeloma: a retrospective study of the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC)","volume":"21","author":"Beaussant","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ejh.12758","article-title":"Outcome of allogeneic transplantation in newly diagnosed and relapsed\/refractory multiple myeloma: long-term follow-up in a single institution","volume":"97","author":"Franssen","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0235","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up","volume":"29","author":"Bj\u00f6rkstrand","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0240","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2004-06-2387","article-title":"Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT","volume":"105","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0245","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.1182\/blood-2011-03-339945","article-title":"Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma","volume":"117","author":"Giaccone","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0250","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/bmt.2011.192","article-title":"Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma","volume":"47","author":"Ringden","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0255","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0260","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.1182\/blood-2011-12-395970","article-title":"Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence","volume":"119","author":"Arai","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0265","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/j.bbmt.2015.07.012","article-title":"Phase II study of nonmyeloablative allogeneic bone marrow transplantation for B cell lymphoma with post-transplantation rituximab and donor selection based first on non-HLA factors","volume":"21","author":"Kanakry","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0270","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome\u2013positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0275","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clml.2014.12.005","article-title":"Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation","volume":"15","author":"Antar","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0280","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.bbmt.2014.09.007","article-title":"Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0285","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.aaf2288","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","author":"Str\u00f8nen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0290","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/imt.10.20","article-title":"Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects","volume":"2","author":"Bouchlaka","year":"2010","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0295","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0300","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2011-04-348292","article-title":"Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial","volume":"118","author":"Kneppers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0305","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bbmt.2014.04.014","article-title":"Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation","volume":"20","author":"Alsina","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0310","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2009-07-231092","article-title":"Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors","volume":"114","author":"Koreth","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0315","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3324\/haematol.12184","article-title":"High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma","volume":"93","author":"El-Cheikh","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2017.07.003_bib0320","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbmt.2012.10.032","article-title":"Bortezomib plus dexamethasone followed by escalating donor lymphocyte infusions for patients with multiple myeloma relapsing or progressing after allogeneic stem cell transplantation","volume":"19","author":"Montefusco","year":"2013","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117305724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879117305724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:59:45Z","timestamp":1761058785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879117305724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1083879117305724"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.003","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2017.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}